Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Boehringer Ingelheim and the EFSD call for grant applications in diabetes research  Join our daily free Newsletter

MENAFN Press - 23/01/2013

No. of Ratings : 0
Add to Mixx!


 


(MENAFN Press) Dubai, United Arab Emirates - Wednesday, January 23rd 2013

New research programme unveiled by Boehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD) invites European diabetes research projects to apply for funding.

The Boehringer Ingelheim and EFSD diabetes partnershiphas opened submissions for diabetes research grant applications from across Europe. In a collaboration which aims to stimulate and accelerate European research in diabetes, the EFSD/Boehringer Ingelheim European Diabetes Research Programmes have dedicated more than 2.5 million euros over three years to support research projects targeting specific areas of interest.

"Diabetes affects more than 371 million people worldwide and diabetes remains undiagnosed in up to 50% of cases," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim."We are delighted to partner with the EFSD on this initiative and hope the grant encourages and supports new research in the field of diabetes."

The joint diabetes grant programme will focus on two areas of interest in order to achieve the goals and objectives of the programmes and will welcome proposals which target the following:

1. Regulations of secretion and/or function of non-insulin peptides from the endocrine pancreas. (Basic research)

2. Mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes. (Clinical Research)
The EFSD/Boehringer Ingelheim European Diabetes Research Programmeswill consider funding of basic research projects up to 100,000 euros in total for projects lasting up to 2 years, and clinical research projects up to 400,000 euros in total for projects up to 3 years in duration. Funding applications for research projects will be accepted until 1 April 2013.

"The EFSD is proud to collaborate once again with Boehringer Ingelheim on this important research initiative," said Dr. Viktor Joergens, Executive Director and Vice Director, EFSD. "Ensuring sufficient funding for diabetes research in Europe is vital and we hope that this partnership leads the way to provide invaluable contributions to diabetes research."

Commenting on the Initiative, Mr. Karim El Alaoui, Boehringer Ingelheim Managing Director for Middle East and North Africa, said "the initiative supports Boehringer Ingelheim commitment towards serving humankind through research. The MENA region has the highest comparative prevalence of diabetes equates to 11.0%,1 so we are hoping that we could implement the initiative in the Middle East region in the near future to be able to add to the disease literature of the region".

Applications are invited from single non-profit institutions or groups of institutions in Europe and will be subject to a scientific review by a specialised and independent committee. The ad hoc committee will review the grant applications on criteria such as significance, approach and innovation.

Researchers who are interested in applying for a grant can download an application form from
www.EuropeanDiabetesFoundation.org.

The deadline for submissions is 1 April 2013 and the anticipated award date is in June 2013.


About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.As a central element of its culture, Boehringer Ingelheim pledges to act with social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.For more information please visit www.boehringer-ingelheim.com About DiabetesAn estimated 371 million people worldwide have Type 1 and Type 2 Diabetes.2 Type 2 Diabetes is the most common type, accounting for an estimated 90% of all diabetes cases.3 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.4

 






  MENA News Headlines


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help